Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer's disease mouse model.

Campagna J, Spilman P, Jagodzinska B, Bai D, Hatami A, Zhu C, Bilousova T, Jun M, Elias CJ, Pham J, Cole G, LaDu MJ, Jung ME, Bredesen DE, John V.

Sci Rep. 2018 Dec 4;8(1):17574. doi: 10.1038/s41598-018-35687-8.

2.

Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease.

Theendakara V, Peters-Libeu CA, Bredesen DE, Rao RV.

Mol Neurobiol. 2018 Jun;55(6):5243-5254. doi: 10.1007/s12035-017-0757-2. Epub 2017 Sep 6. Review.

PMID:
28879423
3.

Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease.

Theendakara V, Bredesen DE, Rao RV.

Mol Cell Neurosci. 2017 Sep;83:83-91. doi: 10.1016/j.mcn.2017.07.002. Epub 2017 Jul 15.

PMID:
28720530
4.

Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment Production.

Poksay KS, Sheffler DJ, Spilman P, Campagna J, Jagodzinska B, Descamps O, Gorostiza O, Matalis A, Mullenix M, Bredesen DE, Cosford ND, John V.

Front Pharmacol. 2017 Feb 15;8:46. doi: 10.3389/fphar.2017.00046. eCollection 2017.

5.

Ayurvedic Profiling of Alzheimer's Disease.

Bredesen DE, Rao RV.

Altern Ther Health Med. 2017 May;23(3):46-50. Epub 2017 Feb 27.

PMID:
28236613
6.

Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on ω-3 supplementation.

Famenini S, Rigali EA, Olivera-Perez HM, Dang J, Chang MT, Halder R, Rao RV, Pellegrini M, Porter V, Bredesen D, Fiala M.

FASEB J. 2017 Jan;31(1):148-160. doi: 10.1096/fj.201600677RR. Epub 2016 Sep 27.

7.

Reversal of cognitive decline in Alzheimer's disease.

Bredesen DE, Amos EC, Canick J, Ackerley M, Raji C, Fiala M, Ahdidan J.

Aging (Albany NY). 2016 Jun;8(6):1250-8. doi: 10.18632/aging.100981.

8.

Netrin-1 Interrupts Amyloid-β Amplification, Increases sAβPPα in vitro and in vivo, and Improves Cognition in a Mouse Model of Alzheimer's Disease.

Spilman PR, Corset V, Gorostiza O, Poksay KS, Galvan V, Zhang J, Rao R, Peters-Libeu C, Vincelette J, McGeehan A, Dvorak-Ewell M, Beyer J, Campagna J, Bankiewicz K, Mehlen P, John V, Bredesen DE.

J Alzheimers Dis. 2016 Mar 8;52(1):223-42. doi: 10.3233/JAD-151046.

PMID:
27060954
9.
10.

Direct Transcriptional Effects of Apolipoprotein E.

Theendakara V, Peters-Libeu CA, Spilman P, Poksay KS, Bredesen DE, Rao RV.

J Neurosci. 2016 Jan 20;36(3):685-700. doi: 10.1523/JNEUROSCI.3562-15.2016.

11.

Alzheimer's Model Develops Early ADHD Syndrome.

Zhang Q, Du G, John V, Kapahi P, Bredesen DE.

J Neurol Neurophysiol. 2015;6(6):1-6.

12.

sAβPPα is a Potent Endogenous Inhibitor of BACE1.

Peters-Libeu C, Campagna J, Mitsumori M, Poksay KS, Spilman P, Sabogal A, Bredesen DE, John V.

J Alzheimers Dis. 2015;47(3):545-55. doi: 10.3233/JAD-150282.

PMID:
26401691
13.
14.

Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline.

Raji CA, Eyre H, Wei SH, Bredesen DE, Moylan S, Law M, Small G, Thompson PM, Friedlander RM, Silverman DH, Baune BT, Hoang TA, Salamon N, Toga AW, Vernooij MW.

AJNR Am J Neuroradiol. 2015 Oct;36(10):1803-9. doi: 10.3174/ajnr.A4409. Epub 2015 Jun 4. Review.

15.

Dynamic self-guiding analysis of Alzheimer's disease.

Kurakin A, Bredesen DE.

Oncotarget. 2015 Jun 10;6(16):14092-122. Review.

16.

ω-3 Supplementation increases amyloid-β phagocytosis and resolvin D1 in patients with minor cognitive impairment.

Fiala M, Halder RC, Sagong B, Ross O, Sayre J, Porter V, Bredesen DE.

FASEB J. 2015 Jul;29(7):2681-9. doi: 10.1096/fj.14-264218. Epub 2015 Mar 24.

PMID:
25805829
17.

Correction to hunter-killer peptide (HKP) for targeted therapy.

Ellerby HM, Bredesen DE, Fujimura S, John V.

J Med Chem. 2015 Feb 26;58(4):2045. doi: 10.1021/acs.jmedchem.5b00034. Epub 2015 Feb 10. No abstract available.

PMID:
25668572
18.

Reversal of cognitive decline: a novel therapeutic program.

Bredesen DE.

Aging (Albany NY). 2014 Sep;6(9):707-17.

19.

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.

Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G.

Cell Death Differ. 2015 Jan;22(1):58-73. doi: 10.1038/cdd.2014.137. Epub 2014 Sep 19. Review.

20.

Paradoxical effect of TrkA inhibition in Alzheimer's disease models.

Zhang Q, Descamps O, Hart MJ, Poksay KS, Spilman P, Kane DJ, Gorostiza O, John V, Bredesen DE.

J Alzheimers Dis. 2014;40(3):605-617. doi: 10.3233/JAD-130017.

21.

The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model.

Spilman P, Descamps O, Gorostiza O, Peters-Libeu C, Poksay KS, Matalis A, Campagna J, Patent A, Rao R, John V, Bredesen DE.

Brain Res. 2014 Mar 10;1551:25-44. doi: 10.1016/j.brainres.2013.12.029. Epub 2013 Dec 31.

22.

Neuroprotective Sirtuin ratio reversed by ApoE4.

Theendakara V, Patent A, Peters Libeu CA, Philpot B, Flores S, Descamps O, Poksay KS, Zhang Q, Cailing G, Hart M, John V, Rao RV, Bredesen DE.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18303-8. doi: 10.1073/pnas.1314145110. Epub 2013 Oct 21.

23.

AβPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for alzheimer's disease.

Descamps O, Spilman P, Zhang Q, Libeu CP, Poksay K, Gorostiza O, Campagna J, Jagodzinska B, Bredesen DE, John V.

J Alzheimers Dis. 2013;37(2):343-55. doi: 10.3233/JAD-130578.

24.

Next generation therapeutics for Alzheimer's disease.

Bredesen DE, John V.

EMBO Mol Med. 2013 Jun;5(6):795-8. doi: 10.1002/emmm.201202307. Epub 2013 May 23.

25.

mCiRNA-synaptic crystal ball?

Bredesen D.

Aging (Albany NY). 2012 Nov;4(11):732-3. Review.

26.

No consistent bioenergetic defects in presynaptic nerve terminals isolated from mouse models of Alzheimer's disease.

Choi SW, Gerencser AA, Ng R, Flynn JM, Melov S, Danielson SR, Gibson BW, Nicholls DG, Bredesen DE, Brand MD.

J Neurosci. 2012 Nov 21;32(47):16775-84. doi: 10.1523/JNEUROSCI.2414-12.2012.

27.

The small co-chaperone p23 overexpressing transgenic mouse.

Zhang J, Spilman P, Chen S, Gorostiza O, Matalis A, Niazi K, Bredesen DE, Rao RV.

J Neurosci Methods. 2013 Jan 30;212(2):190-4. doi: 10.1016/j.jneumeth.2012.09.022. Epub 2012 Sep 27.

28.

Moonlighting peptides with emerging function.

Rodríguez Plaza JG, Villalón Rojas A, Herrera S, Garza-Ramos G, Torres Larios A, Amero C, Zarraga Granados G, Gutiérrez Aguilar M, Lara Ortiz MT, Polanco Gonzalez C, Uribe Carvajal S, Coria R, Peña Díaz A, Bredesen DE, Castro-Obregon S, del Rio G.

PLoS One. 2012;7(7):e40125. doi: 10.1371/journal.pone.0040125. Epub 2012 Jul 13. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/fc687f18-ce8e-4704-87a5-d6807953204e.

29.

Altering APP proteolysis: increasing sAPPalpha production by targeting dimerization of the APP ectodomain.

Libeu CA, Descamps O, Zhang Q, John V, Bredesen DE.

PLoS One. 2012;7(6):e40027. doi: 10.1371/journal.pone.0040027. Epub 2012 Jun 29.

30.

Ayurvedic medicinal plants for Alzheimer's disease: a review.

Rao RV, Descamps O, John V, Bredesen DE.

Alzheimers Res Ther. 2012 Jun 29;4(3):22. doi: 10.1186/alzrt125.

31.

Do proteomics analyses provide insights into reduced oxidative stress in the brain of an Alzheimer disease transgenic mouse model with an M631L amyloid precursor protein substitution and thereby the importance of amyloid-beta-resident methionine 35 in Alzheimer disease pathogenesis?

Sultana R, Robinson RA, Lange MB, Fiorini A, Galvan V, Fombonne J, Baker A, Gorostiza O, Zhang J, Cai J, Pierce WM, Bredesen DE, Butterfield DA.

Antioxid Redox Signal. 2012 Dec 1;17(11):1507-14. Epub 2012 Jun 6.

32.

Human embryonic stem cells express elevated levels of multiple pro-apoptotic BCL-2 family members.

Madden DT, Davila-Kruger D, Melov S, Bredesen DE.

PLoS One. 2011;6(12):e28530. doi: 10.1371/journal.pone.0028530. Epub 2011 Dec 9. Erratum in: PLoS One. 2012;7(9). doi:10.1371/annotation/38d5bc7f-42f2-4d1e-b293-1a003bb57812.

33.

Endogenously EGFP-Labeled Mouse Embryonic Stem Cells.

Zhang J, Rao RV, Spilman P, Mangada J, Xie L, Vitelli C, Gorostiza OF, Madden DT, Zeng X, Jin K, Hart MJ, Bredesen DE, Galvan V.

Aging Dis. 2011 Feb;2(1):18-29.

34.

The small chaperone protein p23 and its cleaved product p19 in cellular stress.

Poksay KS, Banwait S, Crippen D, Mao X, Bredesen DE, Rao RV.

J Mol Neurosci. 2012 Feb;46(2):303-14. doi: 10.1007/s12031-011-9574-7. Epub 2011 Jun 21.

35.

Structural and functional alterations in amyloid-β precursor protein induced by amyloid-β peptides.

Libeu CP, Poksay KS, John V, Bredesen DE.

J Alzheimers Dis. 2011;25(3):547-66. doi: 10.3233/JAD-2011-101938.

36.

Induction of the C-terminal proteolytic cleavage of AβPP by statins.

Descamps O, Zhang Q, John V, Bredesen DE.

J Alzheimers Dis. 2011;25(1):51-7. doi: 10.3233/JAD-2011-101857.

PMID:
21422530
37.

Dependence receptors: from basic research to drug development.

Mehlen P, Bredesen DE.

Sci Signal. 2011 Jan 25;4(157):mr2. doi: 10.1126/scisignal.2001521.

PMID:
21266712
38.

Valosin-containing protein gene mutations: cellular phenotypes relevant to neurodegeneration.

Poksay KS, Madden DT, Peter AK, Niazi K, Banwait S, Crippen D, Bredesen DE, Rao RV.

J Mol Neurosci. 2011 Jun;44(2):91-102. doi: 10.1007/s12031-010-9489-8. Epub 2011 Jan 20.

39.

Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: effects of the amyloid-β peptide of amyloid precursor protein.

Robinson RA, Lange MB, Sultana R, Galvan V, Fombonne J, Gorostiza O, Zhang J, Warrier G, Cai J, Pierce WM, Bredesen DE, Butterfield DA.

Neuroscience. 2011 Mar 17;177:207-22. doi: 10.1016/j.neuroscience.2011.01.005. Epub 2011 Jan 9.

40.

Signaling via amyloid precursor-like proteins APLP1 and APLP2.

Orcholski ME, Zhang Q, Bredesen DE.

J Alzheimers Dis. 2011;23(4):689-99. doi: 10.3233/JAD-2010-101470.

PMID:
21178287
41.

Importance of the caspase cleavage site in amyloid-β protein precursor.

Bredesen DE, John V, Galvan V.

J Alzheimers Dis. 2010;22(1):57-63. doi: 10.3233/JAD-2010-100537. Review.

42.

Identification of new modulators and protein alterations in non-apoptotic programmed cell death.

Sperandio S, Poksay KS, Schilling B, Crippen D, Gibson BW, Bredesen DE.

J Cell Biochem. 2010 Dec 15;111(6):1401-12. doi: 10.1002/jcb.22870.

43.

Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease.

Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V.

PLoS One. 2010 Apr 1;5(4):e9979. doi: 10.1371/journal.pone.0009979. Erratum in: PLoS One. 2011;6(11). doi:10.1371/annotation/05c1b976-7eab-4154-808d-0526e604b8eb.

44.

Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein.

Harris JA, Devidze N, Halabisky B, Lo I, Thwin MT, Yu GQ, Bredesen DE, Masliah E, Mucke L.

J Neurosci. 2010 Jan 6;30(1):372-81. doi: 10.1523/JNEUROSCI.5341-09.2010.

45.

Novel mediators of amyloid precursor protein signaling.

Swistowski A, Zhang Q, Orcholski ME, Crippen D, Vitelli C, Kurakin A, Bredesen DE.

J Neurosci. 2009 Dec 16;29(50):15703-12. doi: 10.1523/JNEUROSCI.4351-09.2009.

46.

In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP.

Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, Fombonne J, Gorostiza O, Zhang J, Sultana R, Bredesen DE.

Free Radic Biol Med. 2010 Jan 1;48(1):136-44. doi: 10.1016/j.freeradbiomed.2009.10.035. Epub 2009 Oct 23.

47.

Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain.

Vogt DL, Thomas D, Galvan V, Bredesen DE, Lamb BT, Pimplikar SW.

Neurobiol Aging. 2011 Sep;32(9):1725-9. doi: 10.1016/j.neurobiolaging.2009.09.002. Epub 2009 Oct 13.

48.

Reversal of learning deficits in hAPP transgenic mice carrying a mutation at Asp664: a role for early experience.

Zhang J, Gorostiza OF, Tang H, Bredesen DE, Galvan V.

Behav Brain Res. 2010 Jan 20;206(2):202-7. doi: 10.1016/j.bbr.2009.09.013. Epub 2009 Sep 12.

49.

Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein.

Park SA, Shaked GM, Bredesen DE, Koo EH.

Biochem Biophys Res Commun. 2009 Oct 16;388(2):450-5. doi: 10.1016/j.bbrc.2009.08.042. Epub 2009 Aug 11.

50.

Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence.

Bredesen DE.

Mol Neurodegener. 2009 Jun 26;4:27. doi: 10.1186/1750-1326-4-27.

Supplemental Content

Loading ...
Support Center